Abstract: An improved process for the preparation of high purity Levosimendan includes treatment of Levosimendan crude with an organic acid, adding an organic acid to precipitate Levosimendan and isolating pure Levosimendan from the precipitate. Levosimendan obtained by the improved process is pharmaceutically acceptable with no impurity higher than 0.2 percent.

Abstract: The present invention is directed to pro-drugs of Eliglustat (formula A) and process for the preparation thereof. The present invention is further directed to pharmaceutical composition thereof and method of treatment using the same.

Abstract: A medical treatment system including a treatment chamber, a source of an aqueous mist containing a medication, a source of an oxygen-enriched gas, and a control system adapted to alternately surround a human body part with a mist containing a medication and the oxygen enriched gas, which can be used to treat various skin disorders including infected lesions, bacterial infections such as acne (i.e. Propionibacterium acnes), fungal infections such as Athlete's foot (i.e. fungal genus Trichophyton), conditions associated with hair loss including alopecia as well as ulcerations and frostbite resulting from poor circulation. A method of treating skin disorders is also disclosed, that includes providing a mist containing a medication and enriched oxygen gas to the site being treated as well as providing oxygen to the patient during treatment.

Abstract: A dressing system for cooling skin or a wound site on a subject comprises a dressing having a reservoir for holding a liquid. The dressing may be configured for placement proximate to a postoperative surgical wound site of the subject or on the facial area of the subject. The dressing system includes a cooling chamber external to the dressing configured to cool the liquid. The dressing system includes a pump configured to circulate the liquid between the cooling chamber and the reservoir. The dressing system may include a suction element for applying suction at, or proximate to, the dressing for removing sweat or wound drainage.

Abstract: According to some embodiments, a skin treatment assembly comprises a handpiece comprising a distal end, the handpiece comprising a recess or cavity configured to receive a cartridge or other fluid container, a tip configured to be positioned along the distal end of the handpiece, the tip being configured to contact a skin surface of a subject during use, and at least one rollerball configured to extend to or near the tip, wherein the rollerball is configured to be in fluid communication with an interior of a cartridge or other fluid container secured to the handpiece, wherein the at least one rollerball is configured to contact the skin surface of the subject during use and to facilitate the delivery of fluids to said skin surface as the rollerball is moved relative to said skin surface.

Abstract: Garments and associated methods are disclosed. In examples, a garment includes an absorbent assembly bonded to a body portion. In examples, the absorbent assembly includes an absorbent layer and overlies at least a central region of the body portion. In examples, the absorbent assembly is at least partially bonded to the body portion with elastic bonding film. In examples, the garment is configured to be washed and re-worn numerous times. In examples, a method of manufacturing a garment includes arranging an absorbent assembly over at least the central region of the body portion and bonding the absorbent assembly to the body portion with strips of elastic bonding film and without stitching. In examples, a moisture-absorbent garment includes a body layer supporting an absorbent assembly within a central region and strips of elastic bonding film that bond at least a portion of the absorbent assembly to the body layer without stitching.

Abstract: Pressure control unit for an ophthalmic irrigation/aspiration system having a chamber with an upper part for storing air and a lower part for storing a surgical fluid to be irrigated or aspirated, the pressure control unit including a negative pressure source, a positive pressure source and an adjustable valve arrangement. The adjustable valve arrangement includes a vacuum port connected to the negative pressure source and a pressure port connected to the positive pressure source. The adjustable valve arrangement also includes a main port in controllable fluid communication with the vacuum port and the pressure port and the main port is connected to an upper part of the chamber.

Abstract: The invention relates to the novel products of formula (I): with p, q=0, 1 or 2; R1=phenyl, pyridyl; —(CH2)m—Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; —SO2—Rb; —CO—Re; m=1 or 2; Ra=aryl, heteroaryl, —CO-cycloalkyl, —CO-heterocycloalkyl, —CO—Rb, —C(Rb)?N—ORc, —CO2Rd, —CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF3, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CH3 or CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is and the isomer of configuration R,R these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.

Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.

Abstract: The application is directed to compounds of formula (I): and their salts and solvates, wherein R1, R2, R3, A1, A2, A3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies.

Abstract: The present invention relates to novel thiophene compounds of general Formula I, and their stereoisomers (diastereoisomers, enantiomers), pure or mixed, racemic mixtures, geometrical isomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, solid forms and mixtures thereof along with process for their preparation. The present invention discloses compounds that are useful in the treatment and prevention of autoimmune diseases.

Abstract: A web having a first surface and a second surface, a plurality of apertures extending through the web from the first surface to the second surface, wherein at least a portion of the plurality of apertures are treated with a composition and at least a portion of the apertures are untreated is disclosed. The treated apertures form a plurality of treated aperture zones, and the untreated apertures form a plurality of untreated aperture zones. Each of the plurality of treated aperture zones has one or more apertures, and each of the plurality of untreated aperture zones has one or more apertures. The plurality of treated aperture zones includes between about 25 percent to about 75 percent of the plurality of apertures.

Abstract: An absorbent article can include a bodyside liner that provides a barrier region. The barrier region can be a central portion of the bodyside liner not coupled to the absorbent body. The barrier region can include a first longitudinal side edge and a second longitudinal side edge. The first longitudinal side edge can be coupled to the projection portion of the first containment flap. The second longitudinal side edge can be coupled to the projection portion of the second containment flap. When the absorbent article is in the relaxed configuration and the projection portion of the first containment flap and the projection portion of the second containment flap extend away from the absorbent body, the central portion of the bodyside liner extends away from absorbent body.

Abstract: A package comprising an interior space and an exterior surface may have a plurality of disposable absorbent articles disposed within the interior space of the package. Each of the disposable absorbent articles may have a topsheet; a backsheet; an absorbent core located between the topsheet and the backsheet. The absorbent products may exhibit an In-Bag Stack Height of less about 80 mm as measured according to an In-Bag Stack Height Test.

Abstract: The application relates to a compound of Formula (I): which modulates the activity of TRIM33, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which TRIM33 plays a role.

Abstract: The furo[3,4-b]quinolone compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.

Abstract: An apparatus to maintain an environment over an anterior surface of a patient eye can include an enclosure sized and shaped to be seated about the patient eye to form a cavity within the enclosure. The enclosure can be configured to contain a fluid other than ambient air in contact with the patient eye. The apparatus can include a fluid regulator in communication with the enclosure, where the fluid regulator can be configured to regulate the composition of the fluid contained within the enclosure.

Abstract: Embodiments disclosed herein relate to a base plate and/or a sensor assembly part of an ostomy appliance. In embodiments, the base plate and/or the sensor assembly part comprises a first adhesive layer, a masking element, and a plurality of electrodes. The first adhesive layer includes a stomal opening with a center point and a proximal surface configured to be attached to a skin surface of a user. The masking element is arranged on a distal surface of the first adhesive layer, and is more insulative than the first adhesive layer. Further, the plurality of electrodes are arranged on a distal side of the first adhesive layer. Each electrode includes a sensing part and a conductor part and the masking element is arranged between the conductor parts and the first adhesive layer.

Abstract: A fluid management layer having a basis weight of between about 40 grams per square meter (gsm) and about 120 gsm is described. The fluid management layer has a plurality of absorbent fibers, a plurality of stiffening fibers and a plurality of resilient fibers, wherein the absorbent fibers are present at about 20 percent to about 75 percent by weight, and wherein the integrated, carded, staple fiber, nonwoven has a first side and a second side, and wherein there is a higher number of absorbent fibers on the first side or second side versus the other.

Abstract: The present disclosure is concerned with 2,5-amino-thiazole compounds that are capable of activating NF-?B signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.